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Biologic therapy has not made the breakthrough in the
treatment of patients with systemic lupus erythematosus
(SLE) that it has managed in patients with rheumatoid
arthritis and psoriatic arthritis. However, there are distinct
signs that this form of treatment is going to find a place in
the pantheon of SLE therapy. Based on a better knowledge
of the ethiopathogenesis of lupus drugs, which interfere
with B cell activation notably, Benlysta and Atacicept have
been reported in major clinical trials to be successful in
terms of controlling disease activity and preventing flares
respectively. In addition, although the formal clinical trials
did not meet their primary endpoints (almost certainly
because of problems with the designs of those trials) the
use of B cell depletion in the form of rituximab is widely
accepted and appears to be helpful and highly beneficial
in aspects of lupus ranging from skin disease to severe
proliferative glomerulonephritis.
My colleagues and I have treated 120 lupus patients with
rituximab and have reported that 90% of patients are in
partial or complete remission at six months (Lu et al.
Arthritis Care Res; 2009: 61, 482), though some questions
remained unanswered. For example, why is it in some
patients B cells return within two months and in other
cases it may be many years? In addition, once the B cells
have returned there is a highly variable length of time
before the clinical features return. In spite of disappointing
results with major clinical trials, at least two new clinical
trials using rituximab, are about to start recruiting, the
RING trial for patients with lupus nephritis who failed
conventional therapy at six months and RITUXILUP
which aims to treat lupus patients at the time of diagnosis
with two infusions of rituximab followed by a low dose of
mycophenolate the state of aim avoiding the use of oral
steroids. In an open label study of 50 lupus nephritis
patients given rituximab at the time of diagnosis followed
by low dose mycophenolate, Condon et al (Ann Rheum
Dis 2013. In press) have reported that just two out of
50 patients after two years have required oral steroids.
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